Testing BHV-8000 for early Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old
- You were diagnosed with Parkinson's disease within the last 2 years
- You are not currently taking any Parkinson's disease medication
- You do not smoke or vape
- You do not have another brain condition besides Parkinson's (like essential tremor or multiple system atrophy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This trial tests if a low dose of carbon monoxide (HBI-002) is safe and helpful for people with Parkinson's disease. It requires specific health criteria and stable Parkinson's medication.
This trial tests a new oral medication, VG081821AC, in people with early to mid-stage Parkinson's disease. The goal is to see if it can improve movement symptoms and slow the progression of the condition, and it may offer a new treatment option for those not yet on levodopa.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.